David Barrett - Assembly Biosciences CFO, COO
| ASMB Stock | USD 13.41 0.08 0.60% |
COO
Mr. David J. Barrett CPA, is Chief Financial Officer, Chief Operating Officer of Company. From April 2006 to September 2009, Mr. Barrett served as Chief Financial Officer of NeuroHitech, Inc., a public company focused on developing, marketing and distributing branded and generic pharmaceutical products. From September 2003 to April 2006, Mr. Barrett was the Chief Financial OfficerVice President of Finance of Overture Asset Managers and Overture Financial Services, which, at the time, was a startup asset management firm that assembled investment products and platforms to distribute turnkey and unbundled investment solutions to financial intermediaries and institutional investors. From July 1999 to September 2003, Mr. Barrett was employed as a Manager at Deloitte Touche, LLP. Mr. Barrett also is a director of Coronado Biosciences, Inc., a biopharmaceutical Company since 2015.
| Age | 38 |
| Tenure | 9 years |
| Address | 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 833 509 4583 |
| Web | https://www.assemblybio.com |
David Barrett Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Barrett against Assembly Biosciences stock is an integral part of due diligence when investing in Assembly Biosciences. David Barrett insider activity provides valuable insight into whether Assembly Biosciences is net buyers or sellers over its current business cycle. Note, Assembly Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Assembly Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Barrett six days ago Disposition of 16840 shares by David Barrett of Expensify at 1.47 subject to Rule 16b-3 | ||
David Barrett over a week ago Disposition of 16740 shares by David Barrett of Expensify at 1.48 subject to Rule 16b-3 | ||
David Barrett over a week ago Disposition of 15903 shares by David Barrett of Expensify at 1.56 subject to Rule 16b-3 | ||
David Barrett over a week ago Disposition of 15992 shares by David Barrett of Expensify at 1.55 subject to Rule 16b-3 |
Assembly Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3387) % which means that it has lost $0.3387 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9895) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Assembly Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 130.2 M.Similar Executives
| Found 1 records | COO Age | ||
| Cristina Larkin | Spero Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.34 |
Assembly Biosciences Leadership Team
Elected by the shareholders, the Assembly Biosciences' board of directors comprises two types of representatives: Assembly Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assembly. The board's role is to monitor Assembly Biosciences' management team and ensure that shareholders' interests are well served. Assembly Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assembly Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicole White, Chief Officer | ||
| John McHutchison, President CEO, Director | ||
| Adam Zlotnick, Chief CoFounder | ||
| Uri Lopatin, Vice President - Research & Development, Chief Medical Officer | ||
| Helen Kim, Independent Director | ||
| Myron Holubiak, Independent Director | ||
| Anthony Altig, Independent Director | ||
| Richard Colonno, Chief Scientific Officer | ||
| Thomas Rollins, Chief Development Officer | ||
| Shannon Ryan, Corporate Relations | ||
| Anuj MD, Chief Officer | ||
| David Houck, Senior Vice President - Product Development and Portfolio Management | ||
| AO FRACP, CEO Director | ||
| Jason Okazaki, President CEO | ||
| Uri MD, CoFounder Advisor | ||
| Michele Anderson, Chief Officer | ||
| Dr IV, Chief Officer | ||
| Lee Arnold, Chief Scientific Officer | ||
| Jacqueline Papkoff, Senior Vice President Chief Scientific Officer Microbiome | ||
| Graham Cooper, CFO, COO and Principal Financial Officer and Principal Accounting Officer | ||
| Jeanette Bjorkquist, Executive Treasury | ||
| William Ringo, Non-Executive Chairman of the Board | ||
| Susan Mahony, Director | ||
| Richard DiMarchi, Director | ||
| Miguel Barbosa, Chief Scientific Officer, Head of Microbiome Program | ||
| Steven Knox, Senior Vice President - Clinical Development | ||
| Tharaknath Rao, Head VP | ||
| Mark Auerbach, Independent Director | ||
| MHROD SHRMSCP, Chief Officer | ||
| Derek Small, Co-Founder, CEO and President and Director | ||
| Alan Lewis, Director | ||
| David Barrett, CFO, COO |
Assembly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assembly Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (1.75) % | ||||
| Current Valuation | (57.07 M) | ||||
| Shares Outstanding | 5.48 M | ||||
| Shares Owned By Insiders | 32.96 % | ||||
| Shares Owned By Institutions | 13.15 % | ||||
| Number Of Shares Shorted | 42.59 K | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 1.95 X |
Pair Trading with Assembly Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Assembly Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assembly Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Assembly Stock
| 0.6 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.59 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Assembly Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Assembly Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Assembly Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Assembly Biosciences to buy it.
The correlation of Assembly Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Assembly Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Assembly Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Assembly Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Assembly Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.38) | Revenue Per Share 1.565 | Quarterly Revenue Growth (1.00) | Return On Assets (0.34) | Return On Equity (0.99) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.